Product Name:

Luxturna (voretigene neparvovec)

Categories: Genetic & Advanced Therapies, Neurology, Ophthalmology, Rare Diseases

Discover Savings on Your Medication Access

Trusted concierge service, secure process, and real savings for patients in the U.S.

Table of Contents

Luxturna (voretigene neparvovec-rzyl)

Product Category

Genetic Therapy / Ophthalmology

Brand Name

Luxturna

Generic Name or Biosimilar

No generic or biosimilar available

Active Ingredient

Voretigene neparvovec-rzyl

Prescription Status

Prescription-only; hospital/clinic-based administration

Targeted Conditions

  • Inherited retinal dystrophy due to confirmed biallelic RPE65 mutation
  • Progressive vision loss leading to blindness

Off-Label Usage

  • Other inherited retinal disorders (under research and clinical trials)

(Off-label use must be strictly supervised within a clinical trial or compassionate use program.)

Drug Classification Overview

Luxturna is an adeno-associated viral (AAV) vector-based gene therapy.
It delivers a normal copy of the RPE65 gene directly to retinal cells via subretinal injection, restoring the ability to produce the essential protein required for vision and slowing or reversing progressive vision loss.

Manufacturer in the USA, Mexico, and Canada

USA: Spark Therapeutics, Inc. (a member of the Roche Group)
Mexico: Roche México, S.A. de C.V.
Canada: Roche Canada

Available Strengths and Dosage Forms – United States, Mexico, and Canada

Country Comparison – United States vs Mexico and Canada

  • Administration protocols are equivalent across all regions.
  • Treatment is restricted to certified hospitals with ophthalmology and surgical expertise.
  • Requires specialized cold chain storage and handling prior to injection.

Average Retail Price (Therapy Cost)

Canada: Potential savings of approx. 20–35% vs U.S. therapy costs (depending on reimbursement programs)
Mexico: Potential savings of approx. 25–40% vs U.S. therapy costs (through certified centers)

Therapy costs vary significantly due to hospital-based surgical requirements, specialized handling, and post-treatment monitoring.

Where to Buy USA

  • Restricted to certified U.S. ophthalmology treatment centers approved by Spark/Roche

Patients must be referred by a retinal specialist and meet genetic testing confirmation for RPE65 mutations.

Storage Requirements

  • Luxturna must be stored frozen at ≤ -65°C until thawed for administration.
  • Requires specialized preparation at the hospital pharmacy prior to subretinal injection.

Key Benefits

  • First FDA- and EMA-approved in vivo gene therapy for an inherited disease
  • Restores functional vision in patients with RPE65 mutation-associated retinal dystrophy
  • May prevent progression to complete blindness
  • Single-dose administration with long-lasting effects
  • Breakthrough therapy in ophthalmic genetics

Shipping from Canada

Luxturna is accessible only through certified Canadian hospitals and treatment centers regulated by Health Canada. MedicalMex coordinates patient cases with licensed ophthalmology and genetic therapy centers.

MedicalMex facilitates:

  • Specialist referral and genetic testing coordination
  • Cross-border medical travel logistics
  • Financial and insurance navigation support
  • Case management and bilingual patient support
  • Post-treatment follow-up assistance

Buying from Mexico

In Mexico, Luxturna is available exclusively through certified hospitals under COFEPRIS oversight. MedicalMex partners with licensed centers to coordinate access for eligible patients.

MedicalMex facilitates:

  • Patient travel and lodging support
  • Coordination with licensed ophthalmology specialists
  • Prescription handling and treatment compliance
  • Full case management with follow-up and support

Side Effects

  • Common: Conjunctival hyperemia; Cataract; Increased intraocular pressure; Retinal tears
  • Moderate: Eye inflammation; Macular hole; Reduced visual acuity (temporary)
  • Serious: Endophthalmitis; Retinal detachment; Severe vision loss (rare)

Close post-operative monitoring by an ophthalmologist is required. Prompt management of ocular complications is essential.

Warnings and Precautions

  • Restricted to certified surgical centers with ophthalmology expertise
  • Do not use in patients with active ocular infection or uncontrolled glaucoma
  • Avoid activities that increase intraocular pressure post-surgery
  • Safety in pregnancy and breastfeeding has not been established

Alternative Medications (by Indication)

Currently, no direct pharmacologic alternatives exist for RPE65 mutation-associated retinal dystrophy.
Supportive measures: low-vision aids, mobility training, and enrollment in clinical trials for emerging genetic therapies.

Medication FAQs

Luxturna is a gene therapy for patients with vision loss caused by confirmed biallelic RPE65 mutations. It works by delivering a functional copy of the RPE65 gene to retinal cells.

Luxturna is administered as a one-time subretinal injection in a surgical procedure by a retinal surgeon at a certified center.

Patients with inherited retinal dystrophy due to confirmed RPE65 mutations and sufficient viable retinal cells are eligible.

No. Luxturna does not cure blindness but can significantly improve functional vision and prevent further progression of vision loss.

Yes. It is available in Canada and Mexico through certified treatment centers under Health Canada and COFEPRIS regulation.

Possible risks include ocular infection, cataract, retinal tears, increased intraocular pressure, or retinal detachment.

Clinical data suggest durable benefits for several years after a single treatment, though long-term follow-up is ongoing.

Yes. Luxturna requires a prescription and can only be administered by trained specialists at certified centers.

Yes. MedicalMex coordinates referrals, travel, and logistics for patients seeking Luxturna therapy in Canada or Mexico.

Currently, no pharmacologic alternatives exist. Supportive care and clinical trial participation may be options.